In Stockholm, Sweden on February 10, 2026, KDventures AB (listed as KDV on Nasdaq Stockholm) shared that its portfolio company SVF Vaccines has assigned Raheleh Nassaji as the Chief Executive Officer. Nassaji's role will involve overseeing the advancement of the company's primary vaccine candidate, SVF-001, into phase 1 of clinical development.
